Urine test for prostate cancer; a genetic approach

An experimental new urine test can reveal if men with early prostate cancer will need aggressive therapy or can be left untreated but monitored, UK researchers say. Current prostate-specific antigen (PSA) blood tests cannot do this, meaning many men experience unnecessary worry, investigations and treatment.

The prostate urine risk (PUR) test looks for genetic markers to give a more accurate assessment. Trials in 537 patients suggest it can reliably sort men by risk. It is one of a number of new tests – including other urine-based ones, as well as blood tests and scans – that scientists are pursuing to improve prostate cancer detection.

A combination of checks rather than one single test may ultimately prove to be the best approach, experts say. Dr David Montgomery, from Prostate Cancer UK, said: "More research now needs to be done to see how accurate this is compared to the newer, non-invasive methods being offered, such as multi-parametric MRI scans."



Other news

Upcoming Events


Technological University Dublin
3-4 September 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Lab Innovations

NEC, Birmingham (Hall 12)
30 & 31 October 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Aug 2019

Meet Epredia: introducing a team you already know

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.